Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7795897 | 0.81 | MEN1 (0.50) | DGAT1MAPTBAZ1AKDM4EEGFR | |
| SCHEMBL4576194 | 0.80 | BAZ1A (0.49) | MAPTBAZ1AKDM4ETDP1EGFR | |
| SCHEMBL6608685 | 0.79 | KDM4E (0.61) | MAPTBAZ1AKDM4ETDP1ALDH1A1 | |
| SCHEMBL14337422 | 0.77 | BAZ1A (0.45) | DGAT1MAPTBAZ1AKDM4EEGFR | |
| SCHEMBL14607665 | 0.77 | BAZ1A (0.45) | DGAT1MAPTBAZ1AKDM4EEGFR | |
| SCHEMBL19905516 | 0.77 | EPHX1 (0.47) | DGAT1MAPTKDM4EEGFRALDH1A1 | |
| SCHEMBL8656543 | 0.76 | NPC1 (0.54) | KDM4EEGFRALDH1A1HPGDHSD17B10 | |
| SCHEMBL7795900 | 0.76 | PKN1 (0.64) | MAPTKDM4ETDP1ALDH1A1HPGD | |
| SCHEMBL7485781 | 0.75 | TP53 (0.48) | DGAT1MAPTBAZ1AKDM4EALDH1A1 | |
| SCHEMBL7794733 | 0.75 | SPHK2 (0.54) | KDM4EEGFRALDH1A1HPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435744-B2 | Piperidine derivatives as NMDA receptor antagonists | GEDEON RICHTER VEGYESZETI GYAR RT (HU) | 2008-10-14 | — | — | US | disclosed |
| EP-1409477-B1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2008-09-17 | — | — | EP | disclosed |
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | UCB Biopharma SRL (BE) | 2004-08-12 | — | — | US | disclosed |
| EP-1409477-A1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003010159-A1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | GRIN1, GRIN2D, GRIN2C | DGAT1 4434/4885MAPT 3836/4885BAZ1A 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.